| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 06/03/2008 | CA2536069C Use of green porphyrins in ocular diagnosis and therapy |
| 06/03/2008 | CA2261018C Treatment and diagnosis of cancer |
| 05/29/2008 | WO2008063721A2 Luminescent macrocyclic lanthanide complexes |
| 05/29/2008 | WO2008063559A2 Methods for using optical agents |
| 05/29/2008 | WO2008063371A2 Imaging of activated vascular endothelium using immunomagnetic mri contrast agents |
| 05/29/2008 | WO2008063078A1 Method for managing patients with cancers |
| 05/29/2008 | WO2008028162A3 Methods of screening agents for activity using teleosts |
| 05/29/2008 | WO2008027611A3 Compositions for visualization of vitreous body and methods of using same |
| 05/29/2008 | WO2007138291A3 Novel imaging agents |
| 05/29/2008 | WO2007117573A3 Transgenic mice for identifying and assessing neural stem/ progenitor cells |
| 05/29/2008 | US20080124353 Proteinase k resistant surface protein of neisseria meningitidis |
| 05/29/2008 | US20080124351 Proteinase k resistant surface protein of neisseria meningitidis |
| 05/29/2008 | US20080124337 Immunoglobulin for use in diagnosis, prevention and treatment of neisserial infection; immunootherapeutics |
| 05/29/2008 | US20080124280 Thyroid Hormone Analogs and Methods of Use |
| 05/29/2008 | US20080124279 pectin is crosslinked with a metal cation; drug delivery system; treating colon cancer; orally administrable |
| 05/29/2008 | US20080124278 characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody; useful in the treatment and prevention of diseases that involve undesirable immune responses |
| 05/29/2008 | US20080124277 Human and Mouse Targeting Peptides Identified by Phage Display |
| 05/29/2008 | US20080124276 Synthetic cornea from retinal stem cells |
| 05/29/2008 | US20080124275 Crystalline Form of Fatty Acid Amide Hydrolase (Faah) |
| 05/29/2008 | US20080124272 antibodies against influenza neuraminidase antigens; monoclonal antibody or antigen binding fragment |
| 05/29/2008 | DE102006056024A1 Method for determining and standardizing efficacy of new batch of neurotoxins with already standardized batch, involves carrying out rough estimation of activity of new batch depending on available protein quantity |
| 05/29/2008 | CA2670419A1 Marker genes for use in the identification of chondrocyte phenotypic stability and in the screening of factors influencing cartilage production |
| 05/29/2008 | CA2669556A1 Method for managing patients with cancers |
| 05/28/2008 | EP1925320A2 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
| 05/28/2008 | EP1501552B1 Mr-signal emitting coatings |
| 05/28/2008 | EP1307582B1 Nucleic acid constructs, vascular cells transformed therewith, pharmaceutical compositions and methods utilizing same for inducing angiogenesis |
| 05/28/2008 | EP1087752B1 Method for producing liposomal formulations of active agents |
| 05/28/2008 | CN101189339A Delivery systems and methods for diagnosing and treating cardiovascular diseases |
| 05/28/2008 | CN101185764A Orthotopic transplantation rat liver cancer model and preparing method and application thereof |
| 05/28/2008 | CN100389828C Medicines comprising Rho kinase inhibitor |
| 05/28/2008 | CN100389821C Stabilized liquid polypeptide-containing pharmaceutical composition |
| 05/27/2008 | US7378237 Development of method for screening physiologically active pyrrole imidazole derivative |
| 05/27/2008 | US7378081 Orally administering a positive contrast agent comprising meglumine diatrizoate, sodium diatrizoate; simethicone; famotidine; and aspartame; applying computerized axial tomography to the patient approximately 50 minutes afterwards; side effect reduction, bulk storage, bioavailability |
| 05/27/2008 | US7378080 Detection, measurement, calibration gene expression |
| 05/27/2008 | US7378079 Agents for imaging and diagnostic methods using them |
| 05/27/2008 | US7378078 Chimeric polypeptide comprising bioluminescent/chemiluminescent, kinase and/or silencing domains for monitoring efficacy of therapeutic agents |
| 05/27/2008 | US7378056 Circuits for in vivo detection of biomolecule concentrations using fluorescent tags |
| 05/22/2008 | WO2008060399A2 X-ray contrast agents comprising a metal chelate and a polyhalogenated phenol, thiophenol, resorcinol, thioresorcinol or dithioresorcinol |
| 05/22/2008 | WO2008059835A1 Metal chelate complex, proton relaxation rate enhancing agent and mri contrast agent |
| 05/22/2008 | WO2007137256A3 Carbon nanotube based imaging agents |
| 05/22/2008 | US20080119699 Method for detecting at least one substance in a metabolic process of a living being and device for carrying out the method |
| 05/22/2008 | US20080119685 Methods for modulating checkpoint activation through TopBP1 |
| 05/22/2008 | US20080118991 Method for isolating and purifying grass pollen allergens |
| 05/22/2008 | US20080118536 A carrier and a grass allergen purified by a combination of hydrophobic interaction chromatography, gel filtration and cation exchange chromatography; antiallergens; improved diagnosis of pollen allergies |
| 05/22/2008 | US20080118440 Reporter conjugate for non-invasive imaging of gene expression in vivo; targeting nucleic acid linked to contrast agent, iron oxide nanoparticle paramagnetic label for magnetic resonance imaging; anti-sense strand hybridizes to portion of messenger RNA encoded by expression gene to be imaged |
| 05/22/2008 | US20080118439 Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism |
| 05/22/2008 | US20080118438 Loss of function mutations in calcium channel polypeptides associated with sudden cardiac death |
| 05/22/2008 | US20080118437 Therapy for bone metastasis; antibody, antisense or siRNA inhibits expression of MCP-1; docetaxel chemotherapy agent; measure level of expression of MCP-1 relative to non-cancerous prostate tissue; determine treatment course |
| 05/22/2008 | US20080118436 Pathological Animal Model For Non-Alcoholic Fatty Hepatitis |
| 05/22/2008 | US20080118435 Composition comprising low density microspheres |
| 05/22/2008 | US20080118434 Genes Commonly Regulated by Different Classes of Antidepressants |
| 05/22/2008 | US20080118432 Predetermined reference range indicates cancer therapy effectiveness; immunoassay; cancer stem cells bound with labeled antibodies specific for cell surface markers prior to detection in flow cytometer; blood, bone marrow, serum, urine, interstitial fluid; breast, brain cancer, acute lymphoid leukemia |
| 05/21/2008 | EP1923702A2 Novel means and methods for the treatment of hearing loss and phantom hearing |
| 05/21/2008 | EP1923075A2 Radiopaque polymeric stents |
| 05/21/2008 | EP1922410A2 Gene disruptions, compositions and methods relating thereto |
| 05/21/2008 | EP1482981B1 Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy |
| 05/21/2008 | EP1392165B1 Method for evaluating efficacy of an anti-aging cosmetic product |
| 05/21/2008 | EP1287130B1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 05/21/2008 | EP1208200B1 Transgenic animal model for neurodegenerative diseases |
| 05/21/2008 | EP1161262B1 SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS |
| 05/21/2008 | EP1064005B1 Urokinase plasminogen activator receptor as a target for diagnosis of micrometastases |
| 05/20/2008 | US7374901 the reduced ubiquinol form has antiaging effect such as the prevention of cellular damage caused by active oxygen and is a good marker for oxidation stress; solvent extraction in isopropyl alcohol from blood sample; reduction; chromatography; accuracy |
| 05/20/2008 | US7374746 diagnostic detection of diseases accompanied with an abnormality of calcium hydroxyapatite using in vivo imaging; contrast agent comprising a fluorescent moiety covalently linked to a bisphosphonate moiety such as, alendronate, clodronate, EB-1053, etidronate, ibandronate, incadronate, neridronate |
| 05/20/2008 | US7374745 Ultrasound contrast agents |
| 05/20/2008 | US7374744 Supplying contrast agent in microbubbles which reradiates ultrasonic frequency; detection |
| 05/20/2008 | US7373782 Polarized gas accumulators and heating jackets and associated gas collection and thaw methods and polarized gas products |
| 05/20/2008 | CA2247151C Microencapsulated fluorinated gases for use as imaging agents |
| 05/20/2008 | CA2169695C Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for the production of pharmaceutical preparations and medicaments containing them |
| 05/20/2008 | CA2169694C Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 05/15/2008 | WO2008057370A2 Means and methods for cytometric therapies |
| 05/15/2008 | WO2008036412A3 Uniform magnetic field spherical coil for mri |
| 05/15/2008 | WO2007106544A3 Chelating conjugates having a substituted aromatic moiety and derivatives thereof |
| 05/15/2008 | WO2007089911A3 Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject |
| 05/15/2008 | US20080114329 Post-biopsy cavity treatment implants and methods |
| 05/15/2008 | US20080113956 Substituted Porphyrins |
| 05/15/2008 | US20080112892 X-Ray Visible Drug Delivery Device |
| 05/15/2008 | US20080112891 Contrast agents; imaging |
| 05/15/2008 | US20080112890 Fetal pulmonary cells and uses thereof |
| 05/15/2008 | US20080112889 Histone deacetylase 8 ( HDAC8); treating T-cell lymphoma by administering a population of autologous T-cells that have been exposed to a selective HDAC8 inhibitor composition ex vivo |
| 05/15/2008 | US20080112888 Igfbp2 biomarker |
| 05/15/2008 | US20080112887 Pancreatitis |
| 05/15/2008 | US20080112886 Engineering shape of polymeric micro- and nanoparticles |
| 05/15/2008 | US20080112885 Has an ingestible capsule that includes a modulator, a spreader, and an acoustic transmitter; and an acoustic receiver; phase shift keying (PSK) modulator |
| 05/15/2008 | US20080112884 Administering to a patient a contrast agent (pyridimifen, fenazaquin) which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging |
| 05/15/2008 | CA2670126A1 Means and methods for cytometric therapies |
| 05/14/2008 | EP1920786A1 Oral preparation useful in measuring capacity to metabolize pyridine |
| 05/14/2008 | EP1920257A1 Optically fluorescent nanoparticles |
| 05/14/2008 | EP1919513A1 Target vector with activable imaging function |
| 05/14/2008 | EP1480683B1 Near infrared fluorescent contrast agent and method for fluorescence imaging |
| 05/14/2008 | CN101180400A Nanoparticles comprising rna ligands |
| 05/14/2008 | CN101178961A water soluble magnetic nanometer crystal with high dissolvability and method of producing the same |
| 05/14/2008 | CN101178359A Fluorescence labeling probiotics bacterial liquid and method for analyzing probiotics absorbing and planting status in intestinal tract |
| 05/13/2008 | US7373197 Methods and devices to expand applications of intraoperative radiation probes |
| 05/13/2008 | US7371877 Glycerol ester derivative |
| 05/13/2008 | US7371744 Photosensitizers for photodynamic therapy; killing tissue, cells; anticancer agents |
| 05/13/2008 | US7371365 Methods for detecting parenchymal plaques in vivo |
| 05/13/2008 | US7371364 Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy |
| 05/13/2008 | US7371225 Method for convection enhanced delivery of therapeutic agents |
| 05/08/2008 | WO2008054824A2 Methods for differential detection of hypoxic tissue in a mammalian subject |
| 05/08/2008 | WO2008054509A2 Methods for assessing cell labeling |